Demonstrates RNA interference targeting hepatic angiotensinogen synthesis with zilebesiran in mild to moderate hypertension, highlighting a novel approach to blood pressure regulation.
Angiotensinogen is the most upstream precursor of the renin-angiotensin-aldosterone system, a key pathway in blood pressure (BP) regulation. Zilebesiran, an investigational RNA interference therapeutic, targets hepatic angiotensinogen synthesis.
No takes yet. Share an insight, caveat, or question.
Bakris et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: